Case Report: Allergic Rhinitis
DOI:
https://doi.org/10.58931/cpct.2023.1321Abstract
Case #1
A 32-year-old female presents to her primary healthcare professional (HCP) with a long history of intermittent nasal congestion, sneezing, rhinorrhea, and itchy eyes. She recalls experiencing these symptoms in high school, but notes that her condition has worsened over the years. Her symptoms were previously present only in the summer; however, they now extend year-round. She reports that her symptoms affect her sleep when she has complete nasal blockage, that she is forced to blow her nose throughout the night, and that the constant wakening leaves her feeling fatigued. She notes that she has “tried everything” in terms of over-the-counter (OTC) medications and that she finds the side effects bothersome. She is requesting allergy testing and has heard that there is “a shot” available.
References
Small P, Frenkiel S, Becker A, Boisvert P, Bouchard J, Carr S, Cockcroft D, Denburg J, Desrosiers M, Gall R, Hamid Q, Hébert J, Javer A, Keith P, Kim H, Lavigne F, Lemièr C, Massoud E, Payton K, Schellenberg B, Sussman G, Tannenbaum D, Watson W, Witterick I, Wright E; The Canadian Rhinitis Working Group. Rhinitis: a practical and comprehensive approach to assessment and therapy. J Otolaryngol. 2007;36(Suppl 1):S5–27. DOI: https://doi.org/10.2310/7070.2006.X002
Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol. 2010 Feb 1;125(2):S103-15. DOI: https://doi.org/10.1016/j.jaci.2009.12.989
Keith P, Desrosiers M, Laister T, et al. The burden of allergic rhinitis in Canada, perspectives of physicians and patients in Canada. Allergy, Asthma Clin Immunol. 2012:8:7. DOI: https://doi.org/10.1186/1710-1492-8-7
Small P, Keith P, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol. 2018;14 (Suppl 2):51. DOI: https://doi.org/10.1186/s13223-018-0280-7
Jackson B, Cleto E, Jeimy S. An emerging allergen: Cannabis sativa allergy in a climate of recent legalization. Allergy Asthma Clin Immunol.2020;16:53. https://doi.org/10.1186/s13223-020-00447-9 DOI: https://doi.org/10.1186/s13223-020-00447-9
Dykewicz MS, Wallace DV, Amroll DJ, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-767.
Fein MN, Fischer DA, O’Keefe AW, Sussman GL. CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol. 2019 Dec;15(1):1-6. DOI: https://doi.org/10.1186/s13223-019-0375-9
Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, Munzel U, Bousquet J. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012 May 1;129(5):1282-9. DOI: https://doi.org/10.1016/j.jaci.2012.01.077
Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of “one linked airway disease”. Ann Allergy Asthma Immunol. 2000 Feb 1;84(2):176-87. DOI: https://doi.org/10.1016/S1081-1206(10)62750-0
Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, Nelson M, Weber R, Bernstein DI, Blessing-Moore J, Khan DA. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011 Jan 1;127(1):S1-55. DOI: https://doi.org/10.1016/j.jaci.2010.09.034
Oralair® Product Monograph. Oakville, ON: Stallergenes Canada Inc.; 2016 Nov 18.
Acarizax® Product Monograph. Hørsholm, Denmark: ALK-Abelló A/S; 2017 Apr 28.
Greenhawt M, Oppenheimer J, Nelson M, Nelson H, Lockey R, Lieberman P, Nowak-Wegrzyn A, Peters A, Collins C, Bernstein DI, Blessing-Moore J. Sublingual immunotherapy: a focused allergen immunotherapy practice parameter update. Ann Allergy Asthma Immunol. 2017 Mar 1;118(3):276-82. DOI: https://doi.org/10.1016/j.anai.2016.12.009
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Canadian Primary Care Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
